Comparison
Efinopegdutide vs. Exenatide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
2055640-93-0
141758-74-9
Molecular weight
no data
4186.6 g/mol
Half-life
115 h
2.4 h
Sequence
modifiziertes, von Oxyntomodulin abgeleitetes Peptid, konjugiert an ein humanes IgG4-Fragment (Verlängerung der Plasma-Halbwertszeit)HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSMechanism of action
Efinopegdutide
Efinopegdutide is an oxyntomodulin-derived peptide acting as a dual agonist at the GLP-1 and glucagon receptors with a relative potency of approximately 2:1 (GLP-1 to glucagon). The GLP-1 component mediates glucose-dependent insulin secretion and modulation of satiety; the glucagon component increases energy expenditure and hepatic fat oxidation, which is proposed to contribute to the observed reduction in liver fat. Conjugation to an IgG4 fragment prolongs the half-life and enables weekly administration.
Exenatide
Exenatide is a 39-amino-acid peptide with about 53% sequence homology to human GLP-1. A glycine substitution at position 2 prevents dipeptidyl-peptidase-IV cleavage and extends the half-life from native GLP-1 (minutes) to about 2.4 hours. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon and delays gastric emptying.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
3
5
of which in humans
3
4
Effects recorded
4
3
Open conflicts
1
1
Documented adverse events
1
2
Legal status
Full entries
Frequently asked questions
- What is the difference between Efinopegdutide and Exenatide?
- Efinopegdutide is classified as "Metabolic", while Exenatide is classified as "Metabolic". Efinopegdutide: Efinopegdutide (MK-6024, formerly JNJ-64565111 / HM12525A) is a once-weekly dual agonist at the GLP-1 and glucagon receptors, developed by Hanmi and Merck. It has been studied for obesity and notably for metabolic liver disease (MASH/NAFLD); a phase-2 trial showed greater liver-fat reduction than semaglutide. Investigational, not approved. Exenatide: Synthetic version of exendin-4, originally isolated from the saliva of the Gila monster (Heloderma suspectum). First GLP-1 receptor agonist, FDA-approved 2005 as Byetta. Weekly depot form Bydureon approved 2012. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Efinopegdutide or Exenatide?
- The highest available evidence level is "Human RCT" for Efinopegdutide and "Human RCT" for Exenatide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Efinopegdutide and Exenatide in Germany and the United States?
- Germany: Efinopegdutide — Unapproved, Exenatide — Prescription. United States: Efinopegdutide — Unapproved, Exenatide — Prescription. These are factual summaries with source and review date on the individual pages.